EVOLUS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
EVOLUS, INC. (EOLS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.19 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-03
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $1.19M, a 60.53% decline from fiscal 2024.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $3.00M, a 34.02% decline from fiscal 2023.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.55M.
- EVOLUS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $1.19M 10-K · filed 2026-03-03 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.00M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $3.00M 10-Q · filed 2024-11-06 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.55M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $4.55M 10-Q · filed 2024-11-06 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $0.00 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $0.00 derived: sum of 2 quarters · filed 2020-10-29 | $0.00 10-Q · filed 2020-10-29 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 derived: sum of 4 quarters · filed 2021-03-25 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $4.54M derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $4.54M derived: sum of 3 quarters · filed 2021-03-25 | $5.57M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $4.54M derived: sum of 2 quarters · filed 2020-10-29 | $5.57M 10-Q · filed 2020-10-29 | $5.57M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $4.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $5.57M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $1.03M 10-Q · filed 2020-05-11 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $0.00 derived: sum of 2 quarters · filed 2019-11-04 | $0.00 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $0.00 10-Q · filed 2019-08-12 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |